Daiichi Sankyo – Patient Worthy

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Post author:Bree Clare
Post published:April 22, 2026
Post category:Small cell lung cancer

Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA's acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According…

Japan Advances Targeted Breast Cancer Treatment: Daiichi Sankyo Seeks Approval for Innovative Therapy After Surgery

Post author:Bree Clare
Post published:March 19, 2026
Post category:Breast Cancer

Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to prevent recurrence in early-stage breast…

Daiichi Sankyo Advances Enhertu for High-Risk Breast Cancer: New Hope After Neoadjuvant Therapy

Post author:Bree Clare
Post published:March 13, 2026
Post category:Breast Cancer

Daiichi Sankyo has taken a significant step forward in expanding treatment options for early-stage breast cancer patients by submitting a supplemental New Drug Application (sNDA) to Japan's Ministry of Health,…

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Japan Advances Targeted Breast Cancer Treatment: Daiichi Sankyo Seeks Approval for Innovative Therapy After Surgery

Daiichi Sankyo Advances Enhertu for High-Risk Breast Cancer: New Hope After Neoadjuvant Therapy

Let’s Work Together!

Keep Up to Date

Learn More